Table 1:
Clinicopathologic characteristics prior to tertiary cytoreduction (N=114)
| Variable | n (%) |
|---|---|
| Age at initial diagnosis, years | |
| Median (range) | 52.4 (23.1-79.2) |
| Origin of disease | |
| Fallopian Tube | 9 (7.9%) |
| Ovarian | 103 (90.4%) |
| Peritoneal | 2 (1.8%) |
| Stage | |
| I | 10 (8.8%) |
| II | 16 (14.0%) |
| III | 76 (66.7%) |
| IV | 12 (10.5%) |
| Grade | |
| Low grade | 14 (12.3%) |
| High grade | 100 (87.7%) |
| Histology | |
| Serous | 86 (75.4%) |
| Endometrioid | 10 (8.8%) |
| Clear Cell | 4 (3.5%) |
| Carcinosarcoma | 3 (2.6%) |
| Mucinous | 5 (4.4%) |
| Other | 2 (1.8%) |
| Mixed | 4 (3.5%) |
| BRCA status (n=66) | |
| Negative | 44 (67%) |
| Any BRCA | 22 (33%) |
| NACT | |
| Received NACT | 4 (3.5%) |
| Underwent PDS | 110 (96.5%) |
| Initial cytoreduction (n=101) | |
| Optimal | 92 (91.1%) |
| Suboptimal | 9 (8.9%) |
| Secondary cytoreduction (n=111) | |
| Complete Gross Resection | 75 (67.6%) |
| Any residual | 36 (32.4%) |
| Time to first recurrence, months | |
| Median (range) | 26.9 (5.2-326.6) |
NACT, neoadjuvant chemotherapy; PDS, primary debulking surgery